Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337

NCT03911973 is registered in ClinicalTrials.gov with Kari Wisinski as lead sponsor.

NCT NCT03911973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03911973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
Lead sponsor
Kari Wisinski
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 17, 2019
Completion date
July 31, 2024
Enrollment
37 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer